Timothy Rolph - Sep 9, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Scientific Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Sep 9, 2022
Transactions value $
$30,488
Form type
4
Date filed
9/13/2022, 09:14 PM
Previous filing
Dec 10, 2021
Next filing
Oct 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Award $21.2K +1.01K +0.41% $21.09 245K Jun 30, 2021 Direct F1
transaction AKRO Common Stock Award $9.25K +1.15K +0.47% $8.03* 246K Jun 30, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Award $0 +29.1K $0.00 29.1K Sep 9, 2022 Common Stock 29.1K $21.10 Direct F3
transaction AKRO Stock Option (Right to Buy) Award $0 +29.1K +100% $0.00 58.1K Sep 13, 2022 Common Stock 29.1K $21.10 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired on June 30, 2021 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 These shares were acquired on June 30, 2022 pursuant to the ESPP in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F3 On December 8, 2021, the Reporting Person was granted an option to purchase 87,221 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 9, 2022, the first performance milestone was achieved, resulting in the vesting of 29,074 shares underlying such option.
F4 On December 8, 2021, the Reporting Person was granted an option to purchase 87,221 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 13, 2022, the second performance milestone was achieved, resulting in the vesting of 29,074 shares underlying such option.